马拉维农村单价轮状病毒疫苗对婴儿腹泻相关死亡率的影响
在马拉维姆钦吉开展基于人群的出生队列研究,纳入2012年1月1日至2015年6月1日出生的48672例活产儿。疫苗引入后婴儿腹泻相关死亡率下降31%(95%CI 1-52,p=0.04),两剂 vs 零剂疫苗对腹泻死亡的有效性为34%(95%CI -28至66,p=0.22)。
要点
- 疫苗引入后10-51周龄婴儿腹泻相关死亡率下降31%(95%CI 1-52,p=0.04)。
- 两剂 vs 零剂疫苗对腹泻相关死亡的有效性为34%(95%CI -28至66,p=0.22)。
- 该农村撒哈拉以南非洲地区婴儿中,RV1与腹泻相关死亡大幅减少相关。
核心结论
- RV1与马拉维农村婴儿腹泻相关死亡的大幅减少相关。
- 这些数据为轮状病毒疫苗规划影响的证据增添了相当分量。
研究设计与样本
- 基于人群的出生队列研究,纳入2012年1月1日至2015年6月1日马拉维中部姆钦吉出生的婴儿,分析存活至10周龄者的数据。
- 共招募48672例活产儿,其中38518例符合疫苗条件,37570例存活至10周龄。
- 通过照护者持有的记录或4月龄和1岁家庭访视时的报告提取个体疫苗接种状态,存活至1岁通过家庭访视确认,死因通过口头尸检确定。
- 采用泊松回归评估影响(1减去疫苗引入前后死亡率比),在符合疫苗条件的婴儿(2012年9月17日及以后出生)中采用Cox回归评估有效性(1减去风险比)。
- 两剂 vs 零剂有效性分析纳入28141例婴儿,其中101例在1岁前发生腹泻相关死亡。
主要发现
- 疫苗引入后腹泻相关死亡率下降31%(95%CI 1-52,p=0.04)。
- 两剂 vs 零剂疫苗对腹泻相关死亡的有效性为34%(95%CI -28至66,p=0.22)。
关键数值与推荐
- 符合疫苗条件婴儿定义为2012年9月17日及以后出生。
- 分析人群为存活至10周龄的婴儿,结局为10-51周龄婴儿腹泻相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 有效性估计的95%CI宽(-28至66),未达统计学显著(p=0.22)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus is a major contributor to child mortality. The effect of rotavirus vaccine on diarrhoea mortality has been estimated in middle-income but not low-income settings, where mortality is high and vaccine effectiveness in reducing admissions to hospital is lower. Empirical population-based mortality studies have not been done in any setting. Malawi introduced monovalent rotavirus vaccine (RV1) in October, 2012. We aimed to investigate the impact and effectiveness of the RV1 vaccine in reducing diarrhoea-associated mortality in infants aged 10-51 weeks. METHODS: In this population-based cohort study, we included infants born between Jan 1, 2012, and June 1, 2015, in Mchinji, Central Malawi and analysed data on those surviving 10 weeks. Individual vaccination status was extracted from caregiver-held records or report at home visits at 4 months and 1 year of age. Survival to 1 year was confirmed at home visit, or cause of death ascertained by verbal autopsy. We assessed impact (1 minus mortality rate ratio following vs before vaccine introduction) using Poisson regression. Among vaccine-eligible infants (born from Sept 17, 2012), we assessed effectiveness (1 minus hazard ratio) using Cox regression. FINDINGS: Between Jan 1, 2012, and June 1, 2015, we recruited 48 672 livebirths in Mchinji, among whom 38 518 were vaccine-eligible and 37 570 survived to age 10 weeks. Two-dose versus zero-dose effectiveness analysis included 28 141 infants, of whom 101 had diarrhoea-associated death before 1 year of age. Diarrhoea-associated mortality declined by 31% (95% CI 1-52; p=0·04) after RV1 introduction. Effectiveness against diarrhoea-mortality was 34% (95% CI -28 to 66; p=0·22). INTERPRETATION: RV1 was associated with substantial reduction in diarrhoea-associated deaths among infants in this rural sub-Saharan African setting. These data add considerable weight to evidence showing the impact of rotavirus vaccine programmes. FUNDING: Wellcome Trust and GlaxoSmithKline Biologicals.
引用
- Bar-Zeev N, King C, Phiri T, et al. Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study. Lancet Glob Health. 2018. PMID: 30103981. doi:10.1016/S2214-109X(18)30314-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。